acute myeloid leukemia in elder patients
Conditions
Interventions
Case series:decitabine, cytarabine, aclarubicin, granulocyte colony-stimulating factor
Sponsors
The First Affiliated Hospital of Nanjing Medical Hospital, Jiangsu Province Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Men and women, aged between 60 to 75 years (non-APL); 2. ECOG performance status (PS) score 0-2; 3. Adequate hepatic funcetion defined as: (1) Total bilirubin 60ml/min; (4) Myocardial enzyme <2.0 times the institutional ULN; (5) cardiac ejection fraction in the normal range; 4. Patients understand the disease and voluntarily received the study regimen and follow-up; 5. Have signed the informed consent before study.
Exclusion criteria
Exclusion criteria: 1. A serious uncontrolled cardiac, renal or hepatic insufficiency; 2. Concurrent other malignant tumors other than AML; 3. History of significant bleeding disorder unrelated to AML; 4. A serious infection or metabolic disease; 5. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent; 6. have a large operation within 21 day; 7. The patients with AIDS; 8. Researchers considered not join into the group; 9. Have known to any component of decitabine allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR, PR; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease-free survival; | — |
Countries
China
Contacts
Public ContactLi Jianyong
Outcome results
None listed